Related Experiment Video
Updated: Apr 23, 2026
06:19
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
1.9K
Peptide therapeutics for treating ocular surface infections
1Departments of Ophthalmology and Visual Sciences and Medical Microbiology and Immunology, McPherson Eye Research Institute, University of Wisconsin School of Medicine and Public Health , Madison, Wisconsin.
Summary
Antimicrobial peptides show promise for treating keratitis, a major cause of blindness. Further research is needed to develop these natural compounds against drug-resistant microbial pathogens.
Area of Science:
- Ophthalmology
- Microbiology
- Pharmacology
Background:
- Microbial keratitis, caused by bacteria, viruses, fungi, and parasites, is a significant cause of blindness, especially in developing nations.
- Current antimicrobial therapies for fungal and parasitic keratitis are limited, with issues of efficacy and emerging drug resistance.
- Antimicrobial peptides (AMPs) from nature offer a potential source for novel therapeutics against resistant microbes.
Purpose of the Study:
- To review the current literature on the use of antimicrobial peptides for treating keratitis.
- To identify challenges and limitations associated with peptide-based therapies for ocular infections.
- To discuss future research directions for developing AMPs as anti-keratitis agents.
Main Methods:
- Literature review of studies investigating antimicrobial peptides against ocular pathogens.
- Analysis of peptide activity, efficacy, and safety data from in vitro and in vivo studies.
- Evaluation of the potential for topical application and combination therapy.
Main Results:
- Hundreds of antimicrobial peptides exist, but few have been tested against keratitis-causing pathogens.
- Most tested peptides demonstrated insufficient activity for further development.
- One or two peptides exhibit promising activity, suggesting potential for therapeutic development.
Conclusions:
- Antimicrobial peptides represent a potential new class of drugs for treating keratitis, including cases resistant to conventional antimicrobials.
- Topical application of peptides is suitable for keratitis treatment.
- Further research and development are crucial to overcome current limitations and realize the therapeutic potential of antimicrobial peptides in ophthalmology.
Related Concept Videos
01:23Ophthalmic Drug Delivery Systems
274
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
274
01:22Microbiome of the Eye
66
The human eye has a specialized microbiota that reflects its unique anatomical and immunological environment. This low-biomass microbial community predominantly colonizes the conjunctiva and eyelid margins, playing a vital role in ocular surface homeostasis and defense. Despite its proximity to the richly colonized facial skin, the ocular surface maintains a distinct microbial profile due to continuous mechanical and biochemical defense mechanisms.The conjunctival surface hosts fewer microbial...
66
01:27Open Angle Glaucoma: Treatment
1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
01:28Angle Closure Glaucoma: Treatment
1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.9K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K
01:22Drug Delivery: Miscellaneous Routes
1.1K
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
1.1K